



Final Appraisal Recommendation

Valsartan (Diovan[®]▼)

**Limited submission by:
Novartis Pharmaceuticals UK Limited**

Advice No: 0211 – February 2011

Recommendation of AWMSG

Valsartan (Diovan[®]▼) tablets are not recommended for use within NHS Wales for the treatment of hypertension in children and adolescents 6 to 18 years of age.

The submission contained insufficient evidence for AWMSG to recommend its use.

Additional notes:

Patients currently being treated with valsartan (Diovan[®]▼) tablets for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion and discussions at AWMSG.

Statement of use: No part of this recommendation may be used without the whole of the advice being quoted in full and should be cited as: